Clinical trial · Observational
Characterization of Prostate Cancer With 3T MR
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The long-term goal of this proposal is to provide a pre-treatment evaluation that can assist in the rational selection of patients to undergo appropriate and definitive therapy for prostate cancer. In so doing, it may be possible to further improve the numbers and percentage of cancer patients who receive effective therapy that will cure the disease and maximize their quality of life following therapy. * Aim 1: To evaluate the accuracy of T2W MRI, DCE-MRI and their combined data for staging prostate cancer. * Aim 2: To evaluate the accuracy of MRI in determining tumor volume in the prostate gland. * Aim 3: To evaluate the accuracy of MRI in grading prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Prostate Cancer
- description
- Males with prostate cancer, referred for biopsy or radical prostatectomy
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria 1. Biopsy-proven adenocarcinoma of the prostate. 2. Written documentation from the urologist stating the anticipation that the patient will undergo radical prostatectomy or biopsy of the prostate within six months of MRI. 3. The interval between biopsy and protocol MRI must not be less than 2 weeks. 4. Pathologic specimens from radical prostatectomy must be provided for whole mount analysis. 5. Patients will sign a study-specific consent prior to study entry. 6. Men above the age of 40 years old Exclusion Criteria 1. Patients who because of age, general medical or psychiatric condition, or physiologic status unrelated to the presence of prostate cancer cannot give valid informed consent. 2. Patients unwilling or unable to undergo MRI including patients with contra-indications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips. 3. Patients who cannot tolerate or have contra-indications to ERC insertion; for example, patients who have had a prior abdominoperineal resection of the rectum or have Crohn's disease. 4. Patients with an allergic reaction to latex. 5. Cryosurgery, surgery for prostate cancer including TURP, prostatic radiotherapy, including bradiotherapy for rectal cancer, androgen deprivation therapy, rectal surgery, or alternative medicine prior to radical prostatectomy. 6. Any metallic implant (e.g. hip) or device that might distort local magnetic field and compromise quality of MRI. 7. Radical prostatectomy or biopsy of the prostate not planned to be performed within six (6) months of protocol MRI. 8. Patients who have undergone BCG for bladder cancer. 9. Patients with severe motion artifacts rendering the data unusable. 10. Patients who have an allergic history to gadopentetate dimeglumine administration. 11. Patients with a contraindication to the administration of glucagon (pheochromocytoma, islet pancreatic tumor, or insulin-dependent diabetes) or a prior history of allergic reaction following glucagon administration.
References
Publications (0)
Data not yet available